Presentations

Presentations from Neola Medical

Neola Medical participates in several capital market days and other investor meetings. Below we collect recordings from stock market days and other occasions. The presentations are held in Swedish or English.

Redeye Interview with CEO Hanna Sjöström

Following the release of Neola Medical’s Q4 2024 report, Redeye Equity Research Analyst Gustaf Meyer interviewed CEO Hanna Sjöström to discuss key takeaways, the company’s progress toward the clinical phase, and the upcoming first clinical study on preterm born...

Redeye Interview With CEO Hanna Sjöström Following The Q4 Report 2024

Did you miss Neola Medical’s Q4 report presentation?

Catch up on key insights into Neola Medical’s latest developments as we prepare for clinical studies and continue strengthening our presence in the U.S. market. CEO Hanna Sjöström provides an update on key milestones and strategic progress in the U.S. and looks...

The Q3 report presentation of 2024!

Watch when CEO Hanna Sjöström and CFO David Folkesson presented Neola Medical’s Q3-report of 2024. Learn more about the company’s financial position and the progress from this quarter, toward market approval in the U.S. After the presentation a brief Q&A...

CEO Hanna Sjöström visits Västra Hamnen Möter

The company's product for continuous lung monitoring of preterm born infants is attracting significant international interest. Watch CEO Hanna Sjöström and CEO Oscar Ahlgren at Västra Hamnen TV discuss Neola Medical’s promising study data, the substantial medical...

The Q2 report presentation of 2024!

Did you miss all the exciting updates when CEO Hanna Sjöström and CFO Christian Gyllenberg presented Neola Medical’s Q2-report of 2024 at Finwire TV? Learn more about the company’s financial position and the important key achievements from this quarter, aimed at...

CEO and CFO presents the Q4 report of 2023

Apart from presenting the company’s financial position and the important highlights from this quarter, they also talk more about the significance of this year's achieved milestones, the commercialization plan for market launch, and the focus for 2024. After the...